# **T1130-**09-61

# **Reliable HPLC Method for the Simultaneous Determination of Aspirin and Associated Related Substances in Drug Substance and Tablet Formulation**

Margaret Maziarz, Paul Rainville Waters Corporation, 34 Maple Street, Milford MA CONTACT INFORMATION: Margaret Maziarz@waters.com, Paul Ranville@waters.com

## PURPOSE

To ensure compliance with the current good manufacturing practices (CGMP) regulations, the manufacturers must assure the identity, strength, quality, and purity of the pharmaceutical drug products. This requires establishment of robust analytical test methods that produce reliable and accurate results over the routine use in quality control (QC) laboratory. Aspirin is a common drug for relieving minor aches, pains, fevers, as well as prevention of heart attacks and mini strokes.

In this work, a single HPLC method was developed for the analysis of aspirin active pharmaceutical ingredient (API) and six related substances. Method performance characteristics including system suitability, linearity, accuracy, intraday and interday precisions were assessed in this study.

## METHODS

Aspirin and related substances standard solutions Individual stock standard solutions with related substances and aspirin API were prepared in diluent (60:40 water/acetonitrile with 0.1% formic acid) at 1.0 and 5.0 mg/mL, respectively. The API stock solution was diluted to 0.1 mg/mL and spiked with related substances at 10% level.

## Aspirin sample solutions

Drug tablets containing 81-mg of asprin tablets were crushed and dissolved in diluent (60:40 water/ acetonitrile with 0.1% formic acid) at 1.6 mg/mL of aspirin by sonication for 10 minutes. After extraction, sample test solutions were centrifuged for 10 minutes at 3000 rpm and diluted to 0.1 mg/mL for aspirin assay and to 0.5 mg/mL for impurities analysis, respectively. Solutions were filtered through 0.2 µm Nylon syringe filter prior analysis.

## Method conditions

LC System:	Alliance™ iS HPLC system with TUV detector						
Column:	XSelect™ HSS T3 Column, 4.6 x 150 mm, 3.5 µm (P/N 186004786)						
Column Temp.:	40°C						
Mobile Phase:	A: 0.1% formic acid in water B: 0.1% formic acid in acetonitrile						
Flow Rate:	1.8 mL/min						
	Time (min)	Flow (mL/min)	%A	%В	Curve		
	Initial	1.8	95.0	5.0	6		
Gradient:	0.10	1.8	95.0	5.0	6		
oradient.	7.60	1.8	5.0	95.0	6		
	9.20	1.8	5.0	95.0	6		
	9.30	1.8	95.0	5.0	6		
	13.00	1.8	95.0	5.0	6		
UV Detection:	237 nm						
Injection Vol.:	15.0 µL						
Sample Temp.:	10°C						
Wash solvents:	Purge/Sample Wash: 60:40 water/acetonitrile Seal Wash: 90:10 water/acetonitrile						

# RESULTS

The XSelect HSS T3 column successfully separated all analytes, producing a USP Resolution (USP Rs)  $\geq$  4.9, peak tailing of 1.1 – 1.2, and  $2^{0.30}$ retentivity factor  $(k^*) \ge 2.1$ .

## Method performance


The performance of the method was assessed by measuring system suitability of five replicate injections of the standard mixture for intraday and interday assay analysis. The intraday and interday performance demonstrated excellent repeatability of replicate injections with relative standard deviation (RSD) of the peak areas and retention times ranging from 0.03 to 0.30% and 0.01 to 0.03%, respectively.

Intraday method performance measured against the USP suitability criteria defined in the USP monograph for aspirin tablets<sup>2</sup>. Method met the USP criteria across four sets of data for a one-day analysis. (salicyclic acid: impurity C)

Parameter USP S Requirement <sup>2</sup>		System Suitability 1 Intraday	System Suitability 2 Intraday	System Suitability 3 Intraday	System Suitability 4 Intraday		
Aspirin Assay	N/A	N/A	N/A	N/A	N/A		
Tailing factor for aspirin	Not more than (NMT) 2.0	1.2	1.2	1.2	1.2		
Relative standard deviation (RSD) for aspirin	Not more than (NMT) 2.0%	<ul><li>RSD of areas: 0.07%</li><li>RSD of RT: 0.03%</li></ul>	<ul> <li>RSD of areas: 0.08%</li> <li>RSD of RT: 0.02%</li> </ul>	<ul><li>RSD of areas: 0.03%</li><li>RSD of RT: 0.03%</li></ul>	<ul><li>RSD of areas: 0.03%</li><li>RSD of RT: 0.02%</li></ul>		
Impurities	N/A	N/A	N/A	N/A	N/A		
Resolution between salicyclic acid and aspirin	Not less than (NLT) 2.0	5.3	5.3	5.3	5.3		
RSD for salicyclic acid	Not more than (NMT) 4.0%	<ul><li>RSD of areas: 0.17%</li><li>RSD of RT: 0.02%</li></ul>	<ul><li>RSD of areas: 0.07%</li><li>RSD of RT: 0.02%</li></ul>	<ul><li>RSD of areas: 0.25%</li><li>RSD of RT: 0.02%</li></ul>	<ul><li>RSD of areas: 0.13%</li><li>RSD of RT: 0.02%</li></ul>		
Table1. Intraday method performance.							
terday method performance measured on different days met the USP suitability criteria defined in							

Parameter	USP Requirement <sup>2</sup>	Day 1	Day 2	Day 5	
Aspirin Assay	N/A	N/A	N/A	N/A	
Tailing factor for aspirin	Not more than (NMT) 2.0	1.2	1.2	1.2 • RSD of areas: 0.07% • RSD of RT: 0.02%	
Relative standard deviation (RSD) for aspirin	Not more than (NMT) 2.0%	<ul> <li>RSD of areas: 0.07%</li> <li>RSD of RT: 0.02%</li> </ul>	<ul> <li>RSD of areas: 0.03%</li> <li>RSD of RT: 0.03%</li> </ul>		
Impurities	N/A	N/A	N/A	N/A	
Resolution between salicyclic acid and aspirin	Not less than (NLT) 2.0	5.3	5.3	5.3	
RSD for salicyclic acid	Not more than (NMT) 4.0%	<ul> <li>RSD of areas: 0.14%</li> <li>RSD of RT: 0.02%</li> </ul>	<ul> <li>RSD of areas: 0.24%</li> <li>RSD of RT: 0.03%</li> </ul>	<ul> <li>RSD of areas: 0.15%</li> <li>RSD of RT: 0.02%</li> </ul>	

Table 2. Interday method performance






## $\frac{1}{2}$

# o aaps narm Sc

## Linearity

The calibration plot for aspirin API in the range of 80 to 120% with respect to the API working concentration in the sample preparation of 0.1 mg/mL. The calibration curve of the concentration versus the peak area at each level produced a correlation coefficient ( $R^2$ )  $\ge$  0.999. In addition, the percent deviation of the calculated X values or concentrations ranged from -0.35 to 0.81%.



Calibration curve_%Deviation									
		Name	X Value	Response	Calc. Value	%Deviation			
	1	Aspirin	0.079600	1064112	0.079447	-0.192			
	2	Aspirin	0.079600	1064893	0.079507	-0.117			
	3	Aspirin	0.079600	1064518	0.079478	-0.153			
	4	Aspirin	0.089600	1192734	0.089365	-0.262			
	5	Aspirin	0.089600	1193229	0.089403	-0.220			
	6	Aspirin	0.089600	1193677	0.089438	-0.181			
	7	Aspirin	0.099900	1339905	0.100713	0.814			
	8	Aspirin	0.099900	1337305	0.100513	0.614			
	9	Aspirin	0.099900	1339095	0.100651	0.752			
	10	Aspirin	0.109500	1450279	0.109225	-0.252			
	11	Aspirin	0.109500	1448917	0.109120	-0.347			
	12	Aspirin	0.109500	1449131	0.109136	-0.332			
	13	Aspirin	0.119400	1580940	0.119300	-0.084			
	14	Aspirin	0.119400	1581148	0.119316	-0.070			
	15	Aspirin	0.119400	1582096	0.119389	-0.009			

## Aspirin assay in tablet formulation

The assay results for six samples ranged from 93.4 to 93.6%, meeting the USP acceptance criteria of not less than (NLT) 90.0 and not more than (NMT) 110.0% of the labeled amount of aspirin<sup>2</sup>.




Figure 3. Aspirin assay determination in drug tablet formulation.

### **Related substances analysis**


The related substances content (% impurity) was determined by comparing peak areas of each related substance to the aspirin API peak area. For related substances testing, the drug tablets.

Results met the USP acceptance criteria for salicyclic acid (imp. C): NMT 0.3% and for coated tablets of NMT 3.0%<sup>2</sup>.

Emp <u>çw</u> er 3	Sample Anal	ysis			Empower 3	Sample Analysis
Sample Set Id: 1753					· • • • • •	Sample Set Id: 175
	Result Set Id: 1		Result Set Id: 1926			
	% impurity					% im purity
Impurity F	Response Summa	rized by	Name		Im purity Re	esponse Sum mari zed t
	SampleName	Imp C	Imp D			SampleName
1	Asp Tab 0.5m g	0.906	0.050		1	Asp Drug Sub 0.5mg
2	Asp Tab 0.5m g	0.899	0.047		2	Asp Drug Sub 0.5m g
3	Asp Tab 0.5m g	0.908	0.044		3	Asp Drug Sub 0.5m g
4	Asp Tab 0.5m g	0.907	0.045		4	Asp Drug Sub 0.5m g
5	Asp Tab 0.5m g	0.906	0.045		5	Asp Drug Sub 0.5m g
6	Asp Tab 0.5m g	0.909	0.048		6	Asp Drug Sub 0.5m g
Mean		0.91	0.05		Mean	
Std. Dev.		0.004	0.002		Std. Dev.	
% RSD		0.40	4.42		%RSD	

Figure 4. Percent (%) impurity determination in drug tablet and drug substance formulation.





# CONCLUSIONS

- A single LC method run on the Alliance iS HPLC System was successfully developed for the simultaneous analysis of aspirin active ingredient and six associated related substances.
- Method exhibited excellent system suitability results, linearity, accuracy, intraday and interday performance.
  - Relative standard deviations (RSD) of peak areas and retention times for intraday and interday studies were  $\leq 0.25\%$  and  $\leq 0.03\%$ , respectively.
- Method demonstrated a reliable determination of aspirin assay and related substances (impurities) content in the drug substance and tablet formulations.

## REFERENCES

- 1. 1. <u>Ph. Eur</u>. Monograph. Acetylsalicyclic Acid. The European Pharmacopeia 10.0. 01/2017:0309
- 2. USP Monograph for Aspirin Tablets. United States Pharmacopeia USP43-NF38, official 1-May-2020



Alliance and XSelect are trademarks of Waters Technologies Corporation.